AU771039B2 - A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes - Google Patents

A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes Download PDF

Info

Publication number
AU771039B2
AU771039B2 AU20583/00A AU2058300A AU771039B2 AU 771039 B2 AU771039 B2 AU 771039B2 AU 20583/00 A AU20583/00 A AU 20583/00A AU 2058300 A AU2058300 A AU 2058300A AU 771039 B2 AU771039 B2 AU 771039B2
Authority
AU
Australia
Prior art keywords
group
alkyl
aryl
pharmaceutical composition
alicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU20583/00A
Other languages
English (en)
Other versions
AU2058300A (en
Inventor
Mark D Erion
Paul Vanpoelje
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of AU2058300A publication Critical patent/AU2058300A/en
Application granted granted Critical
Publication of AU771039B2 publication Critical patent/AU771039B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
AU20583/00A 1998-12-24 1999-12-22 A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes Ceased AU771039B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
US60/114718 1998-12-24
PCT/US1999/030713 WO2000038666A2 (en) 1998-12-24 1999-12-22 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
AU2058300A AU2058300A (en) 2000-07-31
AU771039B2 true AU771039B2 (en) 2004-03-11

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20583/00A Ceased AU771039B2 (en) 1998-12-24 1999-12-22 A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes

Country Status (25)

Country Link
EP (1) EP1143955B1 (enExample)
JP (1) JP2003515523A (enExample)
KR (3) KR100689943B1 (enExample)
CN (3) CN100352505C (enExample)
AT (1) ATE300288T1 (enExample)
AU (1) AU771039B2 (enExample)
BR (1) BR9917005A (enExample)
CA (1) CA2354053A1 (enExample)
CZ (1) CZ20012353A3 (enExample)
DE (1) DE69926400T2 (enExample)
DK (1) DK1143955T3 (enExample)
ES (1) ES2246586T3 (enExample)
HK (1) HK1046863B (enExample)
HU (1) HUP0402506A3 (enExample)
ID (1) ID30237A (enExample)
IL (2) IL143569A0 (enExample)
MX (1) MXPA01006511A (enExample)
NO (1) NO20013115L (enExample)
NZ (1) NZ512219A (enExample)
PL (1) PL352756A1 (enExample)
PT (1) PT1143955E (enExample)
RU (2) RU2227749C2 (enExample)
SK (1) SK9172001A3 (enExample)
WO (1) WO2000038666A2 (enExample)
ZA (1) ZA200105016B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
CN1740182A (zh) * 1999-12-22 2006-03-01 症变治疗公司 新的双氨基化膦酸酯前药
EP1607401A1 (en) * 2000-03-08 2005-12-21 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-Bisphosphatase inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CN101301294A (zh) * 2000-07-06 2008-11-12 症变治疗公司 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
WO2004022083A1 (en) * 2002-09-04 2004-03-18 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
TWI349550B (en) 2003-12-26 2011-10-01 A thiazole derivative and adenosine a2a receptor antagonist containing the same
EP1778250A2 (en) * 2004-08-18 2007-05-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
BRPI0519006A2 (pt) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
CN101115483A (zh) * 2004-12-15 2008-01-30 第一三共株式会社 含有FBPase抑制剂的药物组合物
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
WO2008057930A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びage生成阻害剤
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ,インコーポレイテッド Aicaリボシドの放出および血液グルコースの低減のための化合物および方法
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHEEN & LEFEBURE, DRUGS 1998 FEB 55(2) P.225-236 *

Also Published As

Publication number Publication date
HK1046863A1 (zh) 2003-01-30
CN1714866A (zh) 2006-01-04
HUP0402506A2 (hu) 2005-04-28
PL352756A1 (en) 2003-09-08
NO20013115D0 (no) 2001-06-21
KR20070046210A (ko) 2007-05-02
IL143569A0 (en) 2002-04-21
CN101164618A (zh) 2008-04-23
EP1143955A3 (en) 2002-08-28
MXPA01006511A (es) 2004-03-19
KR20060114724A (ko) 2006-11-07
SK9172001A3 (en) 2002-04-04
JP2003515523A (ja) 2003-05-07
CZ20012353A3 (cs) 2001-12-12
HK1046863B (zh) 2008-07-25
ID30237A (id) 2001-11-15
IL143569A (en) 2006-06-11
BR9917005A (pt) 2002-04-02
PT1143955E (pt) 2005-11-30
ES2246586T3 (es) 2006-02-16
WO2000038666A2 (en) 2000-07-06
DK1143955T3 (da) 2005-11-14
HUP0402506A3 (en) 2007-05-29
NZ512219A (en) 2004-12-24
RU2227749C2 (ru) 2004-04-27
NO20013115L (no) 2001-08-24
EP1143955A2 (en) 2001-10-17
KR100689943B1 (ko) 2007-03-08
WO2000038666A3 (en) 2001-11-29
CA2354053A1 (en) 2000-07-06
ATE300288T1 (de) 2005-08-15
CN1350466A (zh) 2002-05-22
DE69926400T2 (de) 2006-05-24
DE69926400D1 (de) 2005-09-01
KR20010099942A (ko) 2001-11-09
CN100352505C (zh) 2007-12-05
RU2003132054A (ru) 2005-04-20
ZA200105016B (en) 2002-09-19
AU2058300A (en) 2000-07-31
EP1143955B1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
EP1143955B1 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
KR100818845B1 (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
AU784370B2 (en) Novel bisamidate phosphonate prodrugs
AU2001273271B2 (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US20030073728A1 (en) Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
HK1075622A (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
AU2003242500C1 (en) Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)